Mono(2-ethyl-5-hydroxyhexyl) phthalate
Based on 1 Customer Validation
Mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) is a biomarker for human exposure to DEHP (HY-B1945). By activating the tryptophan-kynurenine-aryl hydrocarbon receptor (AhR) pathway, mono (2-ethyl-5-hydroxyhexyl) phthalate significantly increases the viability of primary uterine leiomyoma cells and reduces cell apoptosis. Mono (2-ethyl-5-hydroxyhexyl) phthalate correlates with decreased sperm DNA damage. Mono (2-ethyl-5-hydroxyhexyl) phthalate can be used in studies related to uterine leiomyoma.
For research use only. We do not sell to patients.
- Purity: 99.03%
- CAS No.: 40321-99-1
- Formula: C16H22O5
- Molecular Weight:294.34
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Drug Metabolite Library
HY-L098
-
Human Metabolite Library
HY-L123
-
Cell Death Library
HY-L162
-
MCE Bioactive Compound Library
HY-L001V
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Biological Activity
Mono(2-ethyl-5-hydroxyhexyl) phthalate (0.16-16 μM; 48-72 h) enhances the viability and reduces the apoptosis level of primary human uterine leiomyoma smooth muscle cells, with the most significant effect observed at the moderate dose of 1.6 μM[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 48 h) significantly reduces the apoptotic cell population in primary human uterine leiomyoma smooth muscle cells[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 72 h) causes a slight, statistically insignificant increase in the proportion of primary human uterine leiomyoma smooth muscle cells in the S phase[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 24 h) significantly increases the nuclear localization level of AHR in primary human uterine leiomyoma smooth muscle cells, which is comparable to that induced by the potent AHR agonist TCDD[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 8 h) significantly upregulates the mRNA levels of CYP1A1, CYP1B1, AHR, SLC7A5 and SLC7A8 in primary human uterine leiomyoma smooth muscle cells, and (1.6 μM; 24 h) significantly upregulates the mRNA level of TDO2 in these cells[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 72 h) significantly increases the cellular levels of tryptophan and kynurenine in primary human uterine leiomyoma smooth muscle cells[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 24 h) significantly increases the protein level of SLC7A5 in primary human uterine leiomyoma smooth muscle cells[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 72 h) enhances the viability and reduces the apoptosis level of primary human uterine leiomyoma smooth muscle cells, and these effects can be abolished by small interfering RNA (siRNA)-mediated knockdown of aryl hydrocarbon receptor (AHR) or treatment with the AHR antagonist CH223191[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 72 h) increases the viability and reduces the apoptosis level of primary human uterine leiomyoma smooth muscle cells, while siRNA-mediated knockdown of the tryptophan transporters SLC7A5 and SLC7A8 abrogates these effects[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (1.6 μM; 72 h) increases the viability and reduces the apoptosis level of primary human uterine leiomyoma smooth muscle cells, while siRNA-mediated knockdown of the tryptophan catabolic enzyme TDO2 significantly attenuates these effects[1].
Mono(2-ethyl-5-hydroxyhexyl) phthalate (0.16-16 μM; 48-72 h) does not increase the viability of primary human uterine myometrial smooth muscle cells, and its anti-apoptotic effect is weaker or different compared with that in uterine leiomyoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 40321-99-1
-
Appearance Liquid (Density: 1.160±0.06 g/cm3)
-
Molecular Weight 294.34
-
Formula C16H22O5
-
Color Colorless to light yellow
-
SMILES
O=C(C1=CC=CC=C1C(O)=O)OCC(CC)CCC(O)C
-
Synonyms
MEHHP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 100 mg/mL (339.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Iizuka T, et al. Mono-(2-ethyl-5-hydroxyhexyl) phthalate promotes uterine leiomyoma cell survival through tryptophan-kynurenine-AHR pathway activation. Proc Natl Acad Sci U S A. 2022;119(47):e2208886119. [Content Brief]
[2]. Hauser R, et al. Urinary phthalate metabolites and semen quality: a review of a potential biomarker of susceptibility. Int J Androl. 2008;31(2):112-117. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3974 mL | 16.9872 mL | 33.9743 mL | 84.9358 mL |
| 5 mM | 0.6795 mL | 3.3974 mL | 6.7949 mL | 16.9872 mL | |
| 10 mM | 0.3397 mL | 1.6987 mL | 3.3974 mL | 8.4936 mL | |
| 15 mM | 0.2265 mL | 1.1325 mL | 2.2650 mL | 5.6624 mL | |
| 20 mM | 0.1699 mL | 0.8494 mL | 1.6987 mL | 4.2468 mL | |
| 25 mM | 0.1359 mL | 0.6795 mL | 1.3590 mL | 3.3974 mL | |
| 30 mM | 0.1132 mL | 0.5662 mL | 1.1325 mL | 2.8312 mL | |
| 40 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL | 2.1234 mL | |
| 50 mM | 0.0679 mL | 0.3397 mL | 0.6795 mL | 1.6987 mL | |
| 60 mM | 0.0566 mL | 0.2831 mL | 0.5662 mL | 1.4156 mL | |
| 80 mM | 0.0425 mL | 0.2123 mL | 0.4247 mL | 1.0617 mL | |
| 100 mM | 0.0340 mL | 0.1699 mL | 0.3397 mL | 0.8494 mL |
Mono(2-ethyl-5-hydroxyhexyl) phthalate Related Classifications
HY-133677 Related Classifications
Powered by Bioz